The Open AIDS Journal

ISSN: 1874-6136 ― Volume 13, 2019

Treatment Outcome and Adverse Events of Tenofovir Disoproxil Fumarate Based Regimens as Compared to Zidovudine Based Regimens Among People Living with HIV/AIDS: A Systematic Review and Meta-Analysis of Observational Studies

Adane Teshome Kefale1, *, Tegene Legese Dadi1, Tessema Tsehay Biru1, Teshale Ayele Mega2
1 College of Health Sciences, Mizan-Tepi University, Tepi, Ethiopia
2 Institute of Health Sciences, Jimma University, Jimma, Ethiopia



Findings from different studies report inferior clinical and virologic efficacy with TDF/3TC/NVP. But, some studies show that, there was no statistically significant difference in mortality among ZDV and TDF based regimens. The objective of this review was to systematically identify, appraise and synthesize the best available evidence on efficacy and safety of TDF based regimen as compared to ZDV based regimens.


A three-step search strategy was used to locate published and unpublished studies. First, an initial limited search of google was undertaken followed by analysis of text words. A second extensive search was undertaken. We searched the PubMed, EMBASE, Google Scholar, Medline, and CINHAL. We did the initial search for articles on July 11-18, 2016, and updated the results on May 13, 2017.Third, the reference lists of all identified articles was searched for additional studies.


ZDV based regimens had better outcome on prevention of mortality (OR=1.31, 95%CI (1.14, 1.50), I2 = 0%, Chi2 = 2.51), and lower virologic failure (OR = 1.44, 95% CI [1.18, 1.76], chi2 = 5.91, P= 0.003, I2 =83%) while, TDF based regimens were more tolerable (OR=0.15, 95%CI (0.08, 0.30), I2 = 40%, Chi2 = 3.31). The difference in incidence of opportunistic infection is not significant (OR = 0.83, 95% CI [0.52, 1.32], chi2 = 0.11, P= 0.42, I2 =0%).


There is lower mortality and lower virologic failure in ZDV group, but better safety profile among TDF based regimens.

Keywords: Tenofovir, TDF, Zidovudine, HIV/AIDS, Treatment outcome, ZDV group.

Article Information

Identifiers and Pagination:

Year: 2018
Volume: 12
First Page: 38
Last Page: 52
Publisher Id: TOAIDJ-12-38
DOI: 10.2174/1874613601812010038

Article History:

Received Date: 03/4/2018
Revision Received Date: 01/05/2018
Acceptance Date: 03/05/2018
Electronic publication date: 31/05/2018
Collection year: 2018

Article Metrics:

CrossRef Citations:

Total Statistics:

Full-Text HTML Views: 1624
Abstract HTML Views: 857
PDF Downloads: 497
ePub Downloads: 164
Total Views/Downloads: 3142

Unique Statistics:

Full-Text HTML Views: 643
Abstract HTML Views: 348
PDF Downloads: 200
ePub Downloads: 112
Total Views/Downloads: 1303
Geographical View

© 2018 Kefale et al..

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of pharmacy, College of Health Science, Mizan-Tepi University, Tepi, Ethiopia, Tel: +251921465244; E-mails:;


"Publishing with Bentham Open was a great experience. The timeliness and communication were outstanding. I am hopeful that I will have the opportunity to publish with Bentham Open again in the future."

Dr. Daniel B. Chastain
Pharm.D., AAHIVP, Clinical Pharmacy Specialist, Infectious Diseases, Phoebe Health, USA

SCImago Journal Ranking

SCImago Journal & Country Rank

Browse Contents


Webmaster Contact:
Copyright © 2019 Bentham Open